Gilmore O’Neill, Editas Medicine CEO
January 9, 2023 10:09 AM ESTUpdated 12:18 PM
R&D

Up­dat­ed: Ed­i­tas ed­its pipeline, lays off 20% and says bye to CSO to kick off #JPM23 

Kyle LaHucik

Senior Reporter

One of the ear­ly gene edit­ing hope­fuls, Ed­i­tas Med­i­cine, has strug­gled to keep its ship on the right path. The biotech’s lat­est woes in­clude pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times